Starting off the short Canadian trading week this week on the Daily Dive is that of Jeff Stevens, CEO of Psyched Wellness (CSE: PSYC). Jeff joins us to discuss the latest developments across the psychedelics sector as a whole and coming tailwinds, as well as the current progress that Psyched is making in commercializing the Amanita Muscaria mushroom.
Psyched Wellness is a health and wellness firm largely focused on the Amanita Muscaria mushroom, a mushroom with both functional and psychedelic properties to it. The firm is currently in the process of pre-clinical studies on an extract from the mushroom. Going forward, the company will look to acquire natural health product registration from Health Canada and NDI certification from the FDA to enable the commercialization of supplements based upon the unique fungi.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.